IMIDomics to present DocTIS’ research at the XV Symposium on Bioinformatics
DocTIS continues to advance research into data-driven therapies for immune-mediated inflammatory diseases. As part of this effort, IMIDomics Inc., will present a study at the XV Symposium on Bioinformatics (JBI2025), one of the leading forums for bioinformatics research in Spain and Portugal, to be held in Madrid from 22 to 24 October 2025 at the Escuela Técnica Superior de Ingenieros Industriales, Universidad Politécnica de Madrid.
Sergio H. Martínez, machine learning scientist at IMIDomics Inc., will present the poster “Uncovering combination therapies for immune-mediated inflammatory diseases through systems biology analysis on longitudinal patient data”. Attendees will be able to meet Sergio and discuss his work during the Split B poster sessions:
- Thursday 23 October, 16:45 – 17:15
- Friday 24 October, 11:00 – 11:45
- Friday 24 October, 12:45 – 14:15
Uncovering new therapeutic synergies in IMIDs
This study, developed by all DocTIS scientific partners: Vall d’Hebron Research Institute, VHIR (Sara Marsal), Cardiff University (Ernest Choy), the University of Verona (Giampiero Girolomoni), Charité – Universitätsmedizin Berlin (Britta Siegmund), the Institut d’Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS (Pere Santamaria), the National Center for Genomic Analysis, CNAG (Holger Heyn), IMIDomics Inc. (Manuel Lopez-Figueroa), and the HudsonAlpha Institute for Biotechnology (Richard M. Myers), applies a systems biology approach to identify synergistic drug combinations across multiple immune-mediated inflammatory diseases (IMIDs).
Despite progress with targeted therapies, many IMID patients fail to achieve sustained remission. To address this, researchers analysed bulk and single-cell RNA sequencing (scRNA-Seq) data from 186 patients across six diseases: rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis and systemic lupus erythematosus, at treatment initiation and clinical response.
By integrating longitudinal data and computational models, the team identified anti-TNFalpha and anti-IL6R therapies as a promising combination in rheumatoid arthritis, showing molecular complementarity, validation across independent datasets and potential to overcome treatment resistance.
A premier event for bioinformatics research
The symposium, organised by the National Center for Biotechnology (CNB-CSIC), the Spanish National Cancer Research Center (CNIO), BioData.pt, the Portuguese research infrastructure for Life and Health data and the home of the ELIXIR Portugal node, and the Spanish National Bioinformatics Institute (INB/ELIXIR-ES), serves as a leading forum to showcase and discuss the latest developments in bioinformatics.
Bringing together experts from Spain and Portugal, JBI2025 promotes collaboration between academia and industry, fostering cross-disciplinary dialogue at the intersection of biology, data science and computational innovation.
The inclusion of this work reflects the strong link between systems biology and computational approaches in advancing precision medicine, and this presentation underscores the collaborative spirit of DocTIS, bringing together clinical and computational expertise to accelerate the discovery of more effective treatments for immune-mediated diseases.
Learn more about the event and its full programme at: https://jbi2025.cnb.csic.es
